Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Neurology
•
Behavioral Neurology & Neuropsychiatry
How do you decide when to order blood-based biomarker testing for Alzheimer's disease and which one to choose?
Do you do it in place of CSF testing?
Related Questions
When do you evaluate patients with Parkinson's disease and cognitive decline for concurrent Alzheimer's disease?
How do stroke-risk considerations affect your use of atypical antipsychotics for patients with dementia?
What patient factors most strongly influence your decision to start biologic agents in mild cognitive impairment?
How do you counsel patients interested in carotid endarterectomy for asymptomatic carotid disease as a means to reduce dementia risk?
How do you treat agitation in progressive supranuclear palsy?
How do you utilize FDG PET in the evaluation of dementias?
Is there sufficient evidence yet to support the use of lithium supplementation or prescription in the management of neurodegenerative diseases?
What tools do you use to evaluate for cognitive deficits in young patients?
When is it useful to test for multiple amyloid-related biomarkers for patients undergoing work-up for cognitive impairment?
How do you manage problematic disinhibited behaviors in patients with neurocognitive disorders?
